ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Jazz Grows Rare Disease Portfolio With Gentium Buy

by Lisa M. Jarvis
January 6, 2014 | APPEARED IN VOLUME 92, ISSUE 1

Jazz Pharmaceuticals will pay roughly $1 billion in cash to acquire Gentium, an Italian biotech firm focused on treating rare diseases. Gentium recently received European regulatory approval for Defitelio, a treatment for a condition in which veins in the liver are blocked in people undergoing a stem cell transplant. Jazz says the purchase complements its oncology and hematology portfolio. The deal is expected to close in the first quarter.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment